公开(公告)号：US20240269254A1

公开(公告)日：2024-08-15

申请号：US17282774

申请日：2019-10-04

Applicant: Bavarian Nordic A/S

Inventor： Henning Lauterbach ,  Jose Medina Echeverz ,  Maria Hinterberger

IPC: A61K39/00 ,  A61P35/00

CPC classification number: A61K39/00119 ,  A61K39/001106 ,  A61P35/00 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/55516 ,  C12N2710/24134 ,  C12N2710/24171

Abstract: The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The combination comprises an intravenous administration of a recombinant MVA encoding CD40L and an administration of an antagonist or agonist of an immune checkpoint molecule.

公开(公告)号：US12023373B2

公开(公告)日：2024-07-02

申请号：US17421898

申请日：2020-01-10

Applicant: EXPRES2ION BIOTECHNOLOGIES APS

Inventor： Stine Broch Clemmensen ,  Teit Max Moscote Søgaard ,  Willem Adriaan De Jongh

IPC: A61K39/00 ,  A61K38/17 ,  A61K39/39 ,  A61P31/14 ,  C07K14/71 ,  C12N9/10 ,  C12N15/81 ,  C12N15/85 ,  C12P21/00

CPC classification number: A61K39/001106 ,  A61K38/1741 ,  A61K39/39 ,  A61P31/14 ,  C07K14/71 ,  C12N9/1051 ,  C12N15/815 ,  C12N15/85 ,  C12P21/005 ,  C12Y204/01152 ,  A61K2039/5258 ,  C12Y204/01065

Abstract: Disclosed are immunization antigens that have been glyco-engineered to include non-native glycosylation patterns with a view to enhance their properties as antigens for use in such areas as vaccination and antibody production. Also disclosed are to means and methods for producing the glycomodified antigens as well of methods and uses of the glycomodified antigens.

公开(公告)号：US11998594B2

公开(公告)日：2024-06-04

申请号：US17039312

申请日：2020-09-30

Applicant: CASE WESTERN RESERVE UNIVERISTY

Inventor： Nicole F. Steinmetz ,  Sourabh Shukla

IPC: A61K39/00 ,  A61K39/295 ,  A61K39/39 ,  A61P35/00 ,  C07K14/005 ,  C12N7/00

CPC classification number: A61K39/001106 ,  A61K39/0011 ,  C07K14/005 ,  C12N7/00 ,  A61K2039/5258 ,  A61K2039/54 ,  A61K2039/542 ,  C12N2770/26023 ,  C12N2770/26043 ,  C12N2770/26071

Abstract: An anti-cancer virus composition including an icosahedral-shaped plant virus or virus-like particle linked to a HER2 antigen is described. The anti-cancer virus composition can be used for methods of treating or decreasing the risk of developing a HER2-expressing cancer in a subject by administering to a subject in need thereof an effective amount of the anti-cancer virus composition.

公开(公告)号：US20240131152A1

公开(公告)日：2024-04-25

申请号：US18375788

申请日：2023-10-02

Applicant: Centro de Inmunología Molecular

Inventor： Luis Enrique Fernández Molina ,  Belinda Sánchez Ramírez ,  Audry Fernández Gómez ,  Gretchen Bergado Báez ,  Circe Mesa Pardillo ,  Lisset Chao García ,  Narjara González Suárez ,  Dayana Pérez Martínez ,  Diana Rosa Hernández Fernández ,  Mabel Cruz Rodríguez ,  Ángel Alexis Manso Vargas ,  Vicente Guillermo Verez Bencomo ,  Blanca Idelmis Tolón Murguía ,  Miguel Antonio López López ,  Jesús Arturo Junco Barranco

IPC: A61K39/39 ,  A61K9/51 ,  A61K39/00 ,  A61P35/00

CPC classification number: A61K39/39 ,  A61K9/5161 ,  A61K9/5169 ,  A61K39/001106 ,  A61P35/00 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55572

Abstract: This invention describes ways of obtaining nano-particulated adjuvants formed by different synthetic variants of GM3 ganglioside. Depending on the fine structure of the fatty acid in the ceramide of the synthetic GM3, said adjuvants are able to stimulate specifically and in a specialized way the humoral or cellular immune response against accompanying antigens. Particularly, this invention provides immunogenic vaccine compositions that comprise peptides, polypeptides or proteins and the aforementioned nanoparticles, which are formed through the dispersion of hydrophobic proteins of the outer membrane complex (OMC) of Neisseria meningitidis in solutions containing fully synthetic variants of the GM3 ganglioside.

公开(公告)号：US20230405102A1

公开(公告)日：2023-12-21

申请号：US18311155

申请日：2023-05-02

Applicant: BioNTech US Inc.

Inventor： Michael Steven Rooney

IPC: A61K39/00 ,  A61P35/04 ,  A61P35/00 ,  A61K45/06 ,  C07K14/47 ,  C12N9/00 ,  C07K14/705 ,  C07K4/12

CPC classification number: A61K39/001164 ,  A61P35/04 ,  A61P35/00 ,  A61K39/001103 ,  A61K39/001151 ,  A61K39/001108 ,  A61K39/001107 ,  A61K39/001163 ,  A61K39/001106 ,  A61K39/001162 ,  A61K39/001104 ,  A61K39/0011 ,  A61K45/06 ,  C07K14/4748 ,  A61K39/001102 ,  A61K39/001134 ,  A61K39/001154 ,  C12N9/00 ,  C07K14/47 ,  C07K14/705 ,  C07K4/12 ,  A61K39/001152 ,  A61K2039/812 ,  A61K2039/836 ,  A61K2039/5158 ,  A61K2039/82 ,  A61K2039/505 ,  A61K2039/828 ,  A61K2039/804 ,  A61K38/00

Abstract: The field of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.

公开(公告)号：US20230310562A1

公开(公告)日：2023-10-05

申请号：US18064168

申请日：2022-12-09

Applicant: Danmarks Tekniske Universitet

Inventor： Sine Reker Hadrup ,  Vibeke Mindahl Rafa ,  Søren Nyboe Jakobsen

IPC: A61K39/00 ,  A61P31/22 ,  A61P31/16 ,  A61P35/00 ,  A61K35/17 ,  A61K39/12 ,  A61K39/145 ,  A61K39/245 ,  C12M1/12 ,  C12N5/0783 ,  C12N7/00

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001112 ,  A61K39/001113 ,  A61K39/001114 ,  A61K39/001124 ,  A61K39/001168 ,  A61K39/001182 ,  A61K39/001195 ,  A61K39/12 ,  A61K39/145 ,  A61K39/245 ,  A61P31/16 ,  A61P31/22 ,  A61P35/00 ,  C12M25/14 ,  C12N5/0636 ,  C12N7/00 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/55527 ,  A61K2039/55533 ,  A61K2039/605 ,  A61K2039/6087 ,  A61K2039/645 ,  C12N2501/2302 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2501/50 ,  C12N2533/70 ,  C12N2710/16134 ,  C12N2710/16234 ,  C12N2760/16034

Abstract: The present invention relates to artificial antigen presenting cell (aAPC) scaffolds to provide cells with specific functional stimulation to obtain phenotypic and functional properties ideal to mediate tumor regression or viral clearance. In particular, the scaffolds of the present invention comprise antigens, such as peptide-MHC (pMHC) class I molecules, and specific combinations of cytokines and co-stimulatory molecules to allow effective expansion and functional stimulation of specific T cells.

公开(公告)号：US11684660B2

公开(公告)日：2023-06-27

申请号：US16498929

申请日：2018-03-28

Applicant: OHIO STATE INNOVATION FOUNDATION ,  MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

Inventor： Pravin T. P. Kaumaya ,  Tanios Bekaii-Saab

IPC: A61K38/00 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K16/28

CPC classification number: A61K39/001106 ,  A61K39/001129 ,  A61P35/00 ,  C07K14/70503 ,  C07K16/2803 ,  A61K2039/55566 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/6075

Abstract: Disclosed are compositions related to synthetic PD-1 peptides, chimeric PD-1 peptides, anti-PD-1 antibodies and methods of treating cancers, autoimmune diseases, and Alzheimer's disease using said peptides or antibodies.

公开(公告)号：US11674120B2

公开(公告)日：2023-06-13

申请号：US16087286

申请日：2017-03-22

Applicant: University of Florida Research Foundation, Incorporated

Inventor： Maryam Rahman ,  Duane Mitchell ,  Rolando Lovaton ,  Hassan Azari

IPC: C12N5/0784 ,  A61K39/00

CPC classification number: C12N5/0639 ,  A61K39/0011 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001169 ,  A61K39/001186 ,  A61K39/001192 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/57 ,  C12N2500/46 ,  C12N2501/22 ,  C12N2501/2304

Abstract: Cell-based compositions and methods for targeting and treating human diseases, including cancers and infectious diseases, are provided, wherein exogenous intracellular sarcosine is used for improved delivery of the composition.

公开(公告)号：US20240335472A1

公开(公告)日：2024-10-10

申请号：US18682699

申请日：2022-08-05

Applicant: Gamida Cell Ltd.

Inventor： Yona GEFFEN ,  Aviad PATO ,  Julia RIFMAN

IPC: A61K35/17 ,  A61K39/00 ,  C07K14/725 ,  C07K16/32 ,  C12N5/0783 ,  C12N15/85

CPC classification number: A61K35/17 ,  A61K39/001106 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464406 ,  C07K14/7051 ,  C07K16/32 ,  C12N5/0646 ,  C12N15/85 ,  A61K2039/5156 ,  A61K2239/13 ,  A61K2239/17 ,  A61K2239/21 ,  A61K2239/59 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2500/38 ,  C12N2501/2315 ,  C12N2502/1114 ,  C12N2510/00

Abstract: A composition and method of ex vivo producing natural killer (NK) cells expressing a chimeric antigen receptor (CAR) or a transgenic T cell receptor (tg-TCR) capable of binding HER2 is disclosed. The method comprising: (a) expanding a population of NK cells by a method comprising: (i) culturing the population of NK cells under conditions allowing for cell proliferation, wherein the conditions comprise providing an effective amount of nutrients, serum, IL-15 and nicotinamide; and (ii) supplementing the population of NK cells with an effective amount of fresh nutrients, serum, IL-15 and nicotinamide 5-10 days following step (i) to produce expanded NK cells; so as to obtain an ex vivo expanded population of NK cells, and (b) upregulating expression of a CAR or a tg-TCR capable of binding HER2 in the ex vivo expanded population of NK cells.

公开(公告)号：US20240299518A1

公开(公告)日：2024-09-12

申请号：US18663847

申请日：2024-05-14

Applicant: CENTRO DE INMUNOLOGIA MOLECULAR

Inventor： BELINDA SÁNCHEZ RAMÍREZ ,  GRETCHEN BÁEZ BERGADO ,  NARJARA GONZÁLEZ SUÁREZ ,  MABEL CRUZ RODRÍGUEZ ,  DIANA ROSA HERNÁNDEZ FERNÁNDEZ ,  LISSET CHAO GARCÍA

IPC: A61K39/00 ,  A61P35/00

CPC classification number: A61K39/001106 ,  A61K39/001104 ,  A61P35/00 ,  A61K2039/55555 ,  A61K2039/585 ,  A61K2039/70 ,  A61K2039/82 ,  A61K2039/852

Abstract: The present invention relates to the branch of Biotechnology and Medicine, particularly to a method for the selection and treatment of patients with carcinomas of epithelial origin that co-express the HER1 and HER2 receptors without increased expression of these receptors or with the presence of RAS activating mutations. In particular, this method is based on the application of bivalent vaccine compositions which have as active principle the extracellular domains of the HER1 and HER2 receptors or portions thereof and as an adjuvant the very small proteoliposomes derived from the outer membrane proteins of Neisseria meningitidis and the GM3 ganglioside. This method is useful for the treatment of patients whose expression levels of HER1 and HER2 do not allow the monoclonal antibodies against HER1 and/or HER2 to have a therapeutic effect.